SCHEMBL3013853

SCHEMBL3013853

COc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4C(F)(F)F)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
HSD17B10 Q99714 2/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
IDO1 P14902 1/20 0.45
LMNA P02545 3/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
GBA1 P04062 2/20 0.42
DCTPP1 Q9H773 1/20 0.41
HSD11B1 P28845 2/20 0.41
CHRM4 P08173 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3649927 0.96 MAPT (0.45) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3018880 0.93 KMT2A (0.47) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3012189 0.91 KMT2A (0.48) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3008727 0.89 KMT2A (0.48) MAPTKMT2AMEN1LMNAALOX15
SCHEMBL3021870 0.88 KMT2A (0.46) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3014108 0.88 MAPT (0.49) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3006270 0.88 MAPT (0.51) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3016668 0.87 KMT2A (0.55) MAPTKMT2AMEN1LMNAALOX15
SCHEMBL3014169 0.87 MAPT (0.48) MAPTHSD17B10USP2RECQLKMT2A
SCHEMBL3003842 0.87 KMT2A (0.48) MAPTKMT2AMEN1LMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.